GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (STU:VE11) » Definitions » YoY Rev. per Sh. Growth

Aravive (STU:VE11) YoY Rev. per Sh. Growth

: -79.27% (As of Sep. 2023)
View and export this data going back to 2017. Start your Free Trial

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Aravive's YoY Rev. per Sh. Growth for the quarter that ended in Sep. 2023 was -79.27%.

Aravive's Revenue per Share for the three months ended in Sep. 2023 was €0.03.

Aravive YoY Rev. per Sh. Growth Historical Data

The historical data trend for Aravive's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aravive Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
YoY Rev. per Sh. Growth
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -97.08 119.64 -19.78 10.81 -27.74

Aravive Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
YoY Rev. per Sh. Growth Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 65.66 -45.24 -61.70 -76.00 -79.27

Aravive YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Aravive's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2022 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2022 )
=(Revenue per Share (A: Dec. 2022 )-Revenue per Share (A: Dec. 2021 ))/ | Revenue per Share (A: Dec. 2021 ) |
=(0.237-0.328)/ | 0.328 |
=-27.74 %

Aravive's YoY Rev. per Sh. Growth for the quarter that ended in Sep. 2023 is calculated as:

YoY Rev. per Sh. Growth (Q: Sep. 2023 )
=(Revenue per Share (Q: Sep. 2023 )-Revenue per Share (Q: Sep. 2022 )) / | Revenue per Share (Q: Sep. 2022 )) |
=(0.034-0.164)/ | 0.164 |
=-79.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aravive YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Aravive's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Aravive (STU:VE11) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (STU:VE11) » Definitions » YoY Rev. per Sh. Growth
Comparable Companies
BNTC VYNE ONVO ENZN CMRA INTI GRTX VIRI BRTX TMBR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ARAV:USA VE11:Germany
Address
3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098
Website
https://www.aravive.com
Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.

Aravive (STU:VE11) Headlines

No Headlines